CLYMHIGH SIGNALFINANCIAL10-K

CLYM's cash position deteriorated substantially from $87.2M to $35.7M while the company reduced net losses, creating a critical liquidity timeline concern for this development-stage biotech.

The dramatic cash decline of nearly 60% combined with expanded risk factor language around capital access signals potential funding pressures ahead. While the company showed improved operational efficiency with reduced net losses, the cash burn trajectory suggests CLYM may need to secure additional financing or strategic partnerships within the next 12-18 months to sustain operations.

Comparing 2026-03-05 vs 2025-03-25View on EDGAR →
FINANCIAL ANALYSIS

CLYM's balance sheet shows concerning liquidity trends with cash and equivalents falling sharply to $35.7M while current liabilities increased to $7.0M, though the company demonstrated better cost control with net losses improving to $59.9M from $73.9M. Total assets declined across the board, and stockholders' equity dropped to $160.5M, reflecting the ongoing cash consumption. The financial picture suggests a biotech company burning through capital while making progress on operational efficiency, but facing an accelerating need for external funding.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-59.1%
$87.2M→$35.7M

Cash declined 59.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
+41.6%
$4.9M→$7.0M

Current liabilities surged 41.6% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+37%
$5.3M→$7.3M

Liabilities grew 37% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Assets
Balance Sheet
-31.7%
$154.9M→$105.8M

Current assets declined 31.7% — monitor working capital adequacy and short-term liquidity.

Stockholders Equity
Balance Sheet
-24.3%
$211.9M→$160.5M

Equity decreased 24.3% — buybacks or losses reducing book value, monitor solvency ratios.

Total Assets
Balance Sheet
-22.8%
$217.2M→$167.7M

Total assets contracted 22.8% — asset sales, write-downs, or balance sheet optimization underway.

Net Income
P&L
+19%
-$73.9M→-$59.9M

Net income grew 19% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+17.2%
-$82.0M→-$67.9M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-25
ADDED
As of February 27, 2026, the registrant ha d 47,767,980 shares of common stock, $0.0001 par value per share, outstanding.
(Mabworks); our ability to enter into future collaborations, strategic alliances, or option and license arrangements; and our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act (JOBS Act).
3 Risk Factor Summary Our business is subject to numerous risks and uncertainties, including, among others, the following: We have incurred significant losses since our inception and expect to continue incurring substantial losses for the foreseeable future.
If we are unable to access capital when needed and on acceptable terms, we may be forced to delay, reduce, or discontinue our product candidate development programs, commercialization efforts, or other operations.
Our future success is dependent on the regulatory approval and commercialization of our product candidates, and if we are unable to successfully develop and commercialize our product candidates, or experience any delay in doing so, our business could be materially harmed.
Further, clinical development in immunology and autoimmune diseases presents inherent challenges, such as disease heterogeneity, variable clinical course, and evolving regulatory expectations for clinically meaningful endpoints, any of which may delay or impair our ability to obtain regulatory approval.
If we encounter difficulties enrolling or retaining patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
We face significant competition in an environment of rapid technological change, and our competitors may develop or obtain regulatory approval for products before us or develop products that are safer, less expensive, or more effective than our product candidates, which could impair our commercial prospects.
We are, have been, and may in the future become, involved in litigation that could result in significant costs, divert the attention of management and harm our business.
Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and commercialize our product candidates, if and when approved, and may affect the prices we may charge for such product candidates, if and when approved.
REMOVED
As of March 21, 2025, the registrant ha d 67,475,395 shares of common stock, $0.0001 par value per share, outstanding.
2 Risk Factor Summary Our business is subject to numerous risks and uncertainties, including those risks discussed in further detail below.
These risks include, among others, the following: We have incurred significant losses since our inception and anticipate that we will incur substantial losses for the foreseeable future and may never achieve or maintain profitability.
If we are unable to access capital when needed, it could force us to delay, reduce or terminate our product development programs, commercialization efforts, or other operations.
Our future success is dependent primarily on the regulatory approval and commercialization of our product candidates.
Preclinical and clinical development involves a lengthy, complex and expensive process with an uncertain outcome.
The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of any future clinical trials may not satisfy the requirements of the U.S.
Food and Drug Administration (FDA) or comparable foreign regulatory authorities.
Drug development is highly uncertain, and if we are unable to successfully develop and commercialize our product candidates, or experience significant delays in doing so, our business may be harmed.
We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, less expensive or more advanced or effective than us, which may harm our financial condition and our ability to successfully market or commercialize our product candidates.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →